MaxCyte (MXCT)

Electroporation uses controlled electrical pulses to temporarily open cell membranes, allowing genetic material, proteins or other molecules to enter the cell. MaxCyte’s technology is designed to perform this process at high efficiency while limiting toxicity and preserving cell viability. That combination is important in areas such as immuno-oncology, engineered immune cells, regenerative medicine and genome editing, where the quality and consistency of modified cells can affect research outcomes and clinical manufacturing.

MaxCyte operates as a cell engineering technology business. It generates revenue from instrument and disposable product sales, licenses, research and clinical fees, and program-related payments from strategic platform license customers. Those agreements can provide additional revenue when partners advance development programs or reach regulatory and commercial milestones. The company does not primarily market a single therapeutic product; instead, it supplies enabling technology that can be used across a wide range of cell-based programs.

For investors, MaxCyte represents exposure to the infrastructure layer of advanced therapies. Its opportunity is linked to the growth of cell and gene therapy pipelines, adoption of non-viral and scalable engineering methods, and customer progress through clinical development. Key considerations include research spending, competition from other transfection and cell processing technologies, regulatory requirements for manufacturing, and the pace at which partner programs mature.